PRISM BioLab (206A) · TargetAdvancedLatest Financial results briefing materials (2026-05-18): "Cited as achieved"
Recurring Monetization of Drug Discovery Platform Technologies
First written in FY2024. 3 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-05-18.
5entries
3years
2from disclosures
How it moved
Same theme, other companies
A business model linking early partnering revenue to royalty revenueA theme 19 companies write about · 1 as a headwind · 25 as a tailwind
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
0 other companies' latest entry also says "Cited as achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2025AdvancedAnnual report
「As a result, revenue for the current fiscal year was ¥677.330 million, up 121.6% year on year.」
Revenue was ¥677.330 million, up 121.6% year on year, demonstrating monetization including the release of contract liabilities following the termination of partnered development contracts. - FY2025-H1AdvancedAnnual report
「As a result, revenue for the current interim accounting period was ¥218.676 million, up 89.4% year on year.」
Revenue for the current interim accounting period, centered on the partnered development business, increased 89.4% year on year, demonstrating monetization in quantitative terms. - FY2024First statedAnnual report
「We aim to build a foundation for recurring revenue by continuing to accumulate similar contracts.」
The company is pursuing a revenue base combining upfront payments, joint research income, milestones, and royalties.